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achieved by a hydrogen bond between the C25-hydroxyl
group of 1,25(OH)2D3 and H397 of helix 11 of the recep-
tor [7] and is supported by an additional, less important
hydrogen bond with H305 [8]. In the presence of agonist,
H397 is able to form van der Waals contacts with F422
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FIN-70211 Kuopio of helix 12. This keeps helix 12 in a position that is
optimal for the formation of the charge clamp betweenFinland
E420 (helix 12) and K246 (helix 3) and permits the binding
of the LXXLL NR interaction domain of coactivator (CoA)
proteins into a hydrophobic cleft on the surface of theSummary
VDR-LBD [9]. These CoA proteins in turn contact and
recruit other components of the basal transcriptionalThe 26,23-lactone derivative of 1,25-dihydroxyvita-
min D3, TEI-9647, is a partial antagonist of the of human machinery, resulting in the enhanced transcription of
1,25(OH)2D3 target genes [10].vitamin D receptor (VDR). However, we found that TEI-
9647 in rat cells behaves as a weak VDR agonist. This Most VDR ligands synthesized to date act as agonists
[11]. Notable exceptions to this are the two-side chainbehavior could be mimicked in human cells by the
double mutagenesis of human VDR (specifically C403S analog Gemini and some of its derivatives, which are
conditional inverse agonists [12, 13]. Only two typesand C410N). The increased agonistic action of TEI-
9647 correlates to a gain in the interaction of the VDR of VDR antagonist are known [14]. These are the 25-
carboxylic esters exemplified by ZK159222 [15] andwith coactivator protein and a decreased stabilization
of the antagonistic conformation of the receptor. Mo- ZK168281 [12] and the 26,23-lactone TEI-9647 [16–18].
ZK159222 and TEI-9647 were characterized as partiallecular dynamics simulations indicated that TEI-9647
acts as antagonist of human VDR by reducing the sta- antagonists, whereas ZK168281 is a pure antagonist
[14, 19]. ZK159222 and ZK168281 show a functionalbility of helix 12 of the ligand binding domain. In con-
trast, N410 of the rat VDR stabilized, via backbone affinity to the VDR that is comparable to that of
1,25(OH)2D3, while that of TEI-9647 is at least 10-foldcontacts, the interaction between helices 11 and 12.
This results in TEI-9647 becoming a weak agonist in lower [14]. Molecular dynamics (MD) simulations of the
VDR-LBD complexed with ZK159222 and ZK168281this organism.
suggest that the difference in the effects of these com-
pounds arises from a more drastic displacement of helixIntroduction
12 by ZK168281 than by ZK159222 [19]. In this antago-
nistic conformation, the interaction of the receptor LBDThe nuclear receptor (NR) for the seco-steroid 1,
25(OH)2D3, VDR, is one of the 11 classic endocrine mem- with CoAs is abolished or at least significantly reduced.
Selective antagonism as exhibited by TEI-9647,bers of the NR superfamily that bind their respective
ligands with high affinity (Kd value of 1 nM or lower) [1]. ZK159222, or the synthetic estrogen receptor ligands
tamoxifen and raloxifene appears to be a complex phe-1,25(OH)2D3 is a key player in calcium homeostasis and
bone mineralization [2] and also has antiproliferative and nomenon that arises through the interplay of a number
of factors, such as differential ligand effects on the trans-prodifferentiational effects on various cell types [3]. Like
all NRs, VDR has a highly conserved DNA binding do- activation of the NR, the type of cofactor recruited, as
well as cell and promoter contexts. For example, themain and a ligand binding domain (LBD) which is less
conserved among members of this protein family. The antagonistic function of ZK159222 was shown to de-
pend on the cell-specific ratio between VDR and RXRLBD is formed by 12  helices, and its overall architec-
ture is similar in all NRs [4]. VDR, acting preferentially proteins [20]. So far, the partial antagonism of TEI-9647
has been explained by a reduced interaction of VDRas a heterodimer with the retinoid X receptor (RXR),
with RXR and/or the CoA SRC-1 [18]. An alternativerecognizes specific DNA sequences in promoter regions
explanation involving covalent binding of this ligand toof 1,25(OH)2D3 target genes, referred to as 1,25(OH)2D3
VDR has been excluded in a separate study [21]. Thisresponse elements (VDREs) [5]. Over 3000 synthetic an-
antagonism displays species-specific differences andalogs of the natural hormone 1,25(OH)2D3 have been
was shown to be more potent in human osteosarcomasynthesized. Most of these ligands are believed to inter-
and promyelocytic leukemia cells [16–18]. In contrast toact with the VDR-RXR-VDRE complex. The central ele-
this, in a rat in vivo model, the action of TEI-9647 couldment of this molecular switch is the VDR-LBD [6], which
not convincingly be distinguished from that of a weakcan be stabilized by a 1,25(OH)2D3 analog either in its
VDR agonist [22].agonistic, inverse agonistic, or antagonistic conforma-
In this study, we aimed to reveal the specific mecha-tion. The stabilization of the agonistic conformation of
nisms of TEI-9647 action by using these species-spe-the VDR-LBD is achieved by the repositioning of its
cific differences. We found that the bulky lactone ringmost carboxy-terminal  helix (helix 12). In detail, this is
of this compound disturbs the exact positioning of helix
12 and therefore blocks the interaction with CoA pro-*Correspondence: carlberg@messi.uku.fi
3 These authors contributed equally to this work. teins. Furthermore, in rat cells, we find that the residual
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Figure 1. Species-Specific Differences in the Functional Profile of VDR Antagonists
The two-dimensional structures of 1,25(OH)2D3, ZK168281, and TEI-9647 are shown (A). Luciferase reporter gene assays were performed on
extracts from Ros17/2.8 (rat osteosarcoma), MG-63 (human osteosarcoma), REK (rat epidermal keratinocytes), HaCaT (human immortalized
keratinocytes), and MCF-7 (human breast cancer) cells that were transfected by a reporter gene construct driven by four copies of the rat
ANF DR3-type VDRE (B). Cells were treated for 16 hr with indicated concentrations of 1,25(OH)2D3, ZK168281, or TEI-9647 alone and in
combination. For each condition, luciferase activity was calculated in comparison to induction with the natural agonist. Columns represent
the mean of triplicates, and the bars indicate standard deviation. The numbers above the solvent values indicate the relative basal activity.
A two-tailed, paired Student’s t test was performed, and p values were calculated in reference to maximal stimulation with 1,25(OH)2D3 (*p 
0.05, **p  0.01, ***p  0.001).
agonistic activity of TEI-9647 was higher than that ob- to that of solvent-treated cells. In contrast, at the same
concentration (1 M), TEI-9647 showed significant re-served in human cells. We suggest that this is because
the rodent-specific amino acids S403 and N410 display sidual agonistic activity (lanes 3, 9, 15, 21, and 27), which
was higher in rat (41%–45% of 10 nM 1,25(OH)2D3) thanmore and stronger interactions with TEI-9647 than C403
and C410 in humans. This results in a loss of the antago- in human (12%–15%) cells. The maximal induction of
reporter gene activity through the natural agonist (lanesnist function of TEI-9647 in rodents.
1, 7, 13, 19, and 25) could be significantly reduced by
a 100-fold molar excess of TEI-9647 in human cellsResults and Discussion
(34%–39%, lanes 11, 23, and 29) but not in rat cells
(78%–81%, lanes 5 and 17). Remarkably, the five cellThe functional profile of the VDR antagonists ZK168281
and TEI-9647 were compared in Ros17/2.8 (rat osteosar- lines differ in their relative basal activity and therefore
their maximal inducibility by 1,25(OH)2D3. For example,coma), MG-63 (human osteosarcoma), REK (rat epider-
mal keratinocytes), HaCaT (human immortalized kera- in Ros17/2.8 cells (lane 6) the basal activity was more
than two times higher than in MCF-7 cells (lane 30).tinocytes), and MCF-7 (human breast cancer) cells. For
this purpose, native VDR activity was assayed in the Taken together, the data indicate that TEI-9647 is a
partial antagonist only in human cellular models but notpresence of the appropriate ligand using a luciferase
reporter gene construct driven by four copies of a direct in rat cells. In contrast, ZK168281 is a pure antagonist
in both species.repeat (DR)3-type VDRE derived from the rat atrial natri-
uretic factor (ANF) gene. This construct was transiently The observation of the species-specific difference in
the functional profile of TEI-9647 led us to hypothesizetransfected into the five cell lines, and the relative lucifer-
ase activity was determined after overnight stimulation that it may be caused by amino acid differences in the
VDR of rodent and human. The amino acid sequencesin the presence of the appropriate ligand (Figure 1).
In all cellular systems, ZK168281 was shown to have of whole mouse and rat VDR are 96% identical, whereas
the identities of both rodent VDRs with human VDR isinsignificant agonistic activity (lanes 2, 8, 14, 20, and
26). In combination with the natural agonist (lanes 4, 88%. However, only two amino acids differ between
human and rodent VDR in the region close to the ligand10, 16, 22, and 28), this ligand suppresses the natural
ligand’s inductive effect to a level which is comparable binding pocket and helix 12. These differences occur
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Figure 2. Differences between Rodent and
Human VDR
Amino acid alignment of the C termini of
mouse, rat, and human VDR (A). The only dif-
ferences, C403 and C410 in human VDR, are
highlighted (B). View of the whole LBD of hu-
man VDR complexed with 1,25(OH)2D3. The
 helices are represented by ribbons of C
atoms (helix 11 in green and helix 12 in red),
and only the side chains of C403 and C410
are shown. Detailed view on C403 in helix 11
and C410 in the loop to helix 12 in human VDR
(C). Dashed lines indicate the interactions of
C410. The average structures were collected
from the last 500 ps of 6 ns MD simulations
at 300 K.
at positions 403 and 410, respectively (Figure 2A). The and the double mutation C403S/C410N significantly, in-
creased the agonistic activity of TEI-9647 (comparerodent receptors both carry a serine and an asparagine
residue at these positions, whereas the human VDR has lanes 3, 9, 15, and 21). The relative basal activity (com-
pare lanes 6, 12, 18, and 24) significantly increased intwo cysteines at positions 403 and 410, respectively.
For MD simulations of the human VDR, initial coordi- the same order. Therefore, the mutagenesis of VDR has
only minor effects on the absolute agonistic activity ofnates were obtained from the X-ray crystal structure of
the human VDR LBD-1,25(OH)2D3 complex [7], and the TEI-9647. In VDRwt- and VDRC403S-overexpressing cells
(lanes 5 and 11), TEI-9647 still showed some partialmissing amino acid residues (positions 118, 119, 375–
377, and 424–427) were modeled [19]. The simulations antagonistic action, which was lost in VDRC410N- and
VDRC430S/C410N-overexpressing cells (lanes 17 and 23). In-were performed for 6 ns, and the locations of C403 and
C410 were found to be at the C terminus of helix 11 and terestingly, the profile of VDRC430S/C410N-overexpressing
cells (lanes 19–24) was found to be similar to that of theat a hinge position in the loop between helices 11 and 12,
respectively (Figure 2B). A detailed view of this area of rat cell lines Ros17/2.8 and REK (Figure 1, lanes 1–6
and 13–18). This suggests that, in rodents, TEI-9647the human VDR-LBD shows that C410 makes a single
contact with its peptide bond nitrogen to the carbonyl cannot act as an antagonist because S403 and N410 in
rat VDR provide the receptor with a higher basal activitygroup of P408 and has in this way a minor contribution
to the orientation of the loop between helices 11 and than C403 and C410 in human VDR. However, this seems
not to affect the antagonistic function of ZK168281. We12 (Figure 2C). C403 is rather close to helix 12 (not shown
in Figure 2C). compared the agonistic profile of TEI-9647 and
1,25(OH)2D3 on human VDRwt and VDRC430S/C410N (FigureIn order to test our hypothesis about the critical role
of C403 and C410 in the function of TEI-9647 as a VDR 3B) and found EC50 values of 3–4 nM for the natural
hormone and 21–24 nM for TEI-9647. We conclude fromantagonist, human VDR was mutated stepwise at both
positions to serine and asparagine, respectively. The this that there was no significant effect of the mutagene-
sis on the functional affinity of the receptor. This com-antagonistic profile of ZK168281 and TEI-9647 was
tested in MCF-7 cells, which were overexpressing VDRwt, parison demonstrated that the double mutation reduced
the inducibility by 1,25(OH)2D3, but not by TEI-9647,VDRC403S, VDRC410N, and VDRC430S/C410N (Figure 3). The pro-
file of VDRwt-overexpressing MCF-7 cells (Figure 3A, so that at the maximal concentration used, TEI-9647
reached approximately 40% of the agonistic activity oflanes 1–6) resembled that of endogenous VDR expres-
sion (Figure 1, lanes 25–32), and the ligands ZK168281 the natural hormone.
To further understand the role of positions 403 andand TEI-9647 behaved as a pure antagonist and a partial
antagonist, respectively. The mutagenesis of VDR at 410 in the antagonistic versus the agonistic action of
TEI-9647, supershift assays were performed using in vitropositions 403 and 410 had virtually no effect on the
antagonistic action of ZK168281 (Figure 3A, compare translated wt and mutant VDR, RXR, the rat ANF DR3-
type VDRE, and the bacterially expressed p160 CoAlanes 2, 8, 14, and 20 and lanes 4, 10, 16, and 22). In
contrast, the single mutations C403S and C410N slightly, transcription intermediary factor (TIF)2 (Figure 4). The
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Figure 3. Substituting Rodent Amino Acids into the Human VDR Abolishes TEI-9647-Mediated Antagonism
Luciferase reporter gene assays were performed with extracts from MCF-7 human breast cancer cells that were transfected by a reporter
gene construct driven by four copies of the rat ANF DR3-type VDRE and an expression vector for VDRwt or the indicated VDR mutant. Cells
were treated for 16 hr with indicated concentrations of 1,25(OH)2D3, ZK168281, or TEI-9647, alone and in combination (A) or with graded
concentrations of 1,25(OH)2D3 or TEI-9647 (B). For each condition, luciferase activity was calculated in comparison to induction with the
natural agonist (A) or in reference to solvent control (B). Columns (A) and data points (B) represent the mean of triplicates, and the bars
indicate standard deviation. The numbers above the solvent values (in [A]) indicate the relative basal activity. A two-tailed, paired Student’s
t test was performed, and p values were calculated in reference to maximal stimulation with 1,25(OH)2D3 (*p  0.05, **p  0.01, ***p  0.001).
natural ligand induced a supershift of VDRwt, VDRC403S, bilization of VDR-LBD conformations, limited protease
digestion assays, which report on the flexibility of theVDRC410N, and VDRC430S/C410N with TIF2 (lanes 4, 12, 20, and
28), whereas in the presence of ZK168281 (lanes 6, 14, C-terminal of the VDR, were performed with VDRwt,
VDRC403S, VDRC410N, and VDRC430S/C410N (Figure 5). With22, and 30) or solvent (lanes 2, 10, 18, and 26), no com-
plex with the CoA protein was detectable. TEI-9647 did VDRwt, both ZK168281 and TEI-9647 stabilize a subpop-
ulation of all VDR molecules in the antagonist-specificnot induce a shift with VDRwt (lane 8), only a very faint
CoA complex with VDRC403S (lane 16), a slightly stronger conformation c2 (lanes 3 and 4). Previously we have
found that ZK168281 and TEI-9647 each stabilize slightlyinteraction with VDRC410N (lane 24), and a dominant shift
with VDRC430S/C410N (lane 32). No supershifted material was different antagonistic conformations [14]. As a control,
1,25(OH)2D3 stabilized the agonistic conformation c1observed under any condition when GST-protein was
used instead of the GST-TIF2 fusion protein. Taken to- and to a lower extent the inverse agonistic conformation
c3 (lane 2), whereas in the presence of solvent, only agether, mutating the cysteine residues of human VDR
at positions 403 and 410 into those amino acids present very low amount of the VDR input was stabilized in c1
and c3 (lane 1). The conformation profile of VDRC410Nat the orthologous positions in the rodent VDR increases
the affinity of VDR for CoAs when the receptor binds TEI- (lanes 9–12) resembled that of VDRwt, where both TEI-
9647 and ZK168281 acted as antagonists with this VDR9647. This is not observed for the pure VDR antagonist
ZK168281. This parallels the observation of the func- mutant. In contrast, with VDRC403S and VDRC430S/C410N,
ZK168281 (lanes 7 and 15), but not TEI-9647 (lane 8 andtional assays (Figure 3) and indicates that TEI-9647 shifts
from being an antagonist to a weak agonist when VDR 16), was able to stabilize the antagonistic conformation
c2. This result indicates that TEI-9647 has lost its antag-is mutated at the two critical positions 403 and 410.
The loss of the antagonistic potential of TEI-9647 onistic potential. Since the limited protease digestion
assay primarily reports the flexibility of the C terminusshould also be reflected by a loss of the ligand-mediated
stabilization of the antagonistic LBD conformation. To of the VDR, specifically C-terminal to the trypsin diges-
tion site at R391, the loss of the antagonist-specificmonitor possible changes in the ligand-dependent sta-
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Figure 4. Ligand-Induced Cofactor Interaction Correlates with Action of VDR Antagonists
Supershift experiments were performed with heterodimers of in vitro translated VDRwt or its mutants with RXR that were preincubated in the
presence of bacterially expressed GST (as a control) or GST-TIF2646-926 with 1 M 1,25(OH)2D3, 1 M ZK168281, 1 M TEI-9647, or solvent
and the 32P-labeled rat ANF DR3-type VDRE. Protein-DNA complexes were separated from free probe through 8% nondenaturing polyacrylamide
gels. A representative experiment is shown. NS indicates nonspecific complexes.
conformation reflects a looser packing of the receptor the pure antagonistic profile of ZK168281 [14, 19]. The
lactone ring of TEI-9647 is more bulky than the end of thein the area of the second trypsin digestion site at R402.
We suggest that this occurs because of more flexiblity side chain of the natural hormone and cannot interact
effectively with H397 and H305. Moreover, the carbonylat the end of helix 11, where S403 is located. Therefore,
the results of the limited protease digestion assay indi- group of the lactone ring cannot interact directly with
F422. These observations indicate that steric hindrancecate that the exchange of a sulfhydryl for a hydroxyl
group increases the electronegativity at position 403, plays a role in this ligand’s antagonstic behavior. How-
ever, TEI-9647 lacks an extended side chain and dis-and this in turn reduces the flexibility of helix 12. In
this way, the mutation C403S also contributes to the turbs helix 12 less than ZK168281 (Figure 6C). In fact,
the disturbance of helix 12 by TEI-9647 is so weak thatincreased constitutive activity of the VDR (see Figure
3). In summary, C403, but not C410, appears to be criti- it can be counterbalanced by backbone contacts of
N410 in VDRC430S/C410N with P408 and L404 (Figure 6D).cal for the stabilization of the antagonistic conforma-
tion of VDR by TEI-9647, whereas its stabilization by Therefore, in rodent VDRs the backbone contacts of
their loop amino acid N410 stabilize the helix 11-helixZK168281 was not influenced by either of these two
cysteines. 12 interaction (Figure 6E) so that the LBD of rodent VDR
binds CoA proteins even in the presence of TEI-9647.Further MD simulations (6 ns) were performed with
VDRwt complexed with 1,25(OH)2D3, ZK168281 and TEI- This supports the finding that TEI-9647 behaves as a
weak agonist rather than as an antagonist in rodents.9647 and with VDRC430S/C410N bound by TEI-9647 in order
to understand the basis of the effects of these ligands The differences in the structures of the complexes of
VDRwt and VDRC430S/C410N with TEI-9647 are better illus-have on VDR (Figure 6). The simulations were calculated
with the whole VDR-LBD, but only the ligand and helices trated when the variation of the backbone root-mean-
square deviation (rmsd) of amino acids 393–422 and the11 and 12 are shown. The 25-hydroxyl group of the
natural ligand contacts H397 in helix 11, which in turn distance between the C atoms of T415 and F422 are
monitored over the whole MD simulation period of 6 nsstabilizes the position of helix 12 via an interaction with
F422 (Figure 6A). This keeps the negatively charged (Figure 7). The rmsd can be used to indicate the mobility
of helices 11 and 12 and is inversely proportional to theE420 of helix 12 at an optimal distance (19 A˚) from the
positively charged K246 of helix 3. This enables the stability of helix 12. After 2.5 ns of MD simulation, the
rmsd of the VDRwt-TEI-9647 complex was significantlyformation of the charge clamp that stabilizes the LBD-
CoA interaction (data not shown; compare [19]). In con- higher than that of the complexes of VDRwt with
1,25(OH)2D3 and of VDRC430S/C410N with 1,25(OH)2D3 ortrast, the extended, rigid side chain of ZK168281 dis-
turbs the interaction between H397 and F422 and thus TEI-9647 (Figure 7A). Interestingly, the latter three LBD-
ligand complexes have the same average rmsd, indicat-the stable positioning of helix 12 (Figure 6B). This blocks
the ability to interact with CoA protein and explains ing their comparable ability to stabilize the interaction
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to 10.8 A˚ in the X-ray crystal structure of the VDRwt-
1,25(OH)2D3-complex [7]).
The observation of a significant difference in the con-
stitutive activity of human and rodent VDR was unex-
pected. In human VDR, C410 forms only one hydrogen
bond with the backbone of helix 11, whereas in rodents
N410 makes two additional contacts. In addition, the
increased interaction strength of S403 compared to
C403 supports the effect of N410 in stabilizing helix 12
for an interaction with helix 11. This provides human
VDRC403S/C410N with a more than 2-fold increased ligand-
independent constitutive activity over VDRwt and per-
fectly mimics the reduced agonist inducibility of the rat
versus human wild-type VDR. Although the inducibility
of endogenous rat VDR or overexpressed VDRC403S/C410N
by 1,25(OH)2D3 is reduced, the absolute induction of
the receptor by TEI-9647 is not decreased. This leads
to an apparent doubling of the relative agonistic action
of this ligand. This results in a loss of the antagonistic
action of the compound when combined with the rather
low receptor binding affinity of TEI-9647. Chemical mod-
ifications of TEI-9647, in particular at its 2 position,
significantly increase the VDR binding affinity [23, 24].
These compounds have the potential to act even in
rodents as partial antagonists. The molecular mecha-
nism of the antagonistic action of TEI-9647 in human
cells is not as obvious as that of the 25-carboxylic ester
ZK168281, but the bulky lactone ring of TEI-9647 dis-
turbs the H397-F422 interaction. This destabilizes the
position of helix 12, induces flexibility to the helix, and
makes a stable interaction of the LBD with CoA proteins
unlikely. However, TEI-9647 derivatives with rather bulky
and/or extended substitutents at their 2 position
[23, 24] cannot sit as deep in the ligand binding pocket
as an unsubstituted ligand. This decreases the distance
between the carbonyl group of the lactone ring and F422
and provides the respective compounds with a higher
antagonistic potential than the parental compound.Figure 5. Stabilization of Agonistic and Antagonistic VDR Confor-
mations A mixed agonist/antagonist profile, such as reported
Limited protease digestion assays were performed by preincubating here for TEI-9647 on rodent and human VDR, was also
in vitro translated 35S-labeled wild-type or mutant VDR with DMSO observed for 5,11-cis-diethyl-5,6,11,12-tetra-hydrochy-
(as solvent control) or saturating concentrations (10 M) of sene-2,8-diol on estrogen receptor (ER)  and  [25].
1,25(OH)2D3, ZK168281, or TEI-9647. After digestion with trypsin, With ER this compound acts as an agonist, whereasthe ligand-stabilized VDR conformations c1 (active) and c3 (silent)
on ER it functions as antagonist. This property waswere electrophoresed through 15% SDS-polyacrylamide gels. The
called passive antagonism. In this respect, TEI-9647antagonist-specific conformation c2 is indicated by an asterisk.
Representative experiments are shown. could also be referred to as a passive antagonist.
Significancewith CoA proteins. The peak after 4 ns of the simulation
of VDRwt with 1,25(OH)2D3 is due to a transient confor-
mational change in the loop region (residues 407–414) Agonism and antagonism of NR ligands are closely
related processes. Both types of ligand bind to thebetween helices 12 and 11. The distance between the
C atoms of T415 and F422 measures the length of helix same site in the ligand binding pocket, but agonists
stabilize the position of helix 12, whereas antagonists12 (Figure 7B). An increased length of helix 12 is a sign
of greater flexibility and is inversely proportional to the prevent this stabilization. TEI-9647 binds the ligand
binding pocket of the VDR with lower affinity than theprobability of an interaction with a CoA proteins. In this
view of the structures, the VDRwt-TEI-9647 complex was natural agonist and acts in human cells as a partial
antagonist. In rat cells, the residual agonistic activityshown after 2 ns of simulations to have a significantly
longer and more flexible helix 12 than the complexes of of TEI-9647 is significantly higher than in human cells,
because the rodent-specific amino acids S403 andVDRwt with 1,25(OH)2D3 and of VDRC430S/C410N with 1,
25(OH)2D3 or TEI-9647. Again, the latter two LBD-ligand N410 display more and stronger interactions than
C403 and C410 in humans. The bulky lactone ring ofcomplexes appeared to be identical and had the same
average length of helix 12 (10.7–10.9 A˚, which is close TEI-9647 disturbs the exact positioning of helix 12,
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Figure 6. MD Simulations of LBD-Ligand Complexes
Average structures of VDRwt (A–C) or VDRC403/C410 (D and E) complexed with 1,25(OH)2D3 (A), ZK168281 (B), or TEI-9647 (C–E) were collected
from the last 500 ps of 6 ns MD simulations at 300 K. Please note that the coordinates for the VDR-ZK168281 complex were taken from our
previous publication [19]. The relative position of the ligand in relation to helices 11 and 12 is shown. Detailed view on S403 in helix 11 and
N410 the loop to helix 12 in VDRC403/C410 (D). Dashed lines indicate the backbone interactions of N410 with P408 and L404.
which results in a decreased interaction with CoA pro- increased VDR binding affinity, which in parallel cause
more disturbance to helix 12, have the potential to beteins. However, the displacement of helix 12 by TEI-
effective VDR antagonists.9647 is much weaker than that by the pure antagonist
ZK168281, so that only the 26,23-lactone but not the
Experimental Procedures25-carboxylic ester is affected by the increased inter-
action potential of S403 and N410 in rodent VDR. This Compounds
results in a loss of the antagonist function of TEI- The natural hormone 1,25(OH)2D3 was a kind gift from Dr. Lise
Binderup (LEO Pharma, Ballerup, Denmark), its 25-carboxylic ester9647 in rodents. However, derivatives of TEI-9647 with
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6-well plates (105 cells/ml) and grown overnight in phenol red-free
DMEM supplemented with 5% charcoal-treated fetal bovine serum.
Liposomes were formed by incubating 1 g of the reporter plasmid
and, in indicated cases, 1 g of expression vector for VDR or its
mutants with 10 g N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethyl-
ammonium methylsulfate (DOTAP, Roth, Karlsruhe, Germany) for 15
min at room temperature in a total volume of 100 l. After dilution
with 900 l phenol red-free DMEM, the liposomes were added to
the cells. Phenol red-free DMEM supplemented with 15% charcoal-
treated fetal bovine serum (500 l) was added 4 hr after transfection.
At this time, VDR ligands at the indicated concentrations were also
added. The cells were lysed 16 hr after onset of stimulation using the
reporter gene lysis buffer (Roche Diagnostics, Mannheim, Germany),
and the constant light signal luciferase reporter gene assay was
performed as recommended by the supplier (Canberra-Packard,
Groningen, The Netherlands). The luciferase activities were normal-
ized with respect to protein concentration, and relative values were
calculated relative to that treated with the natural agonist.
Protein Production and Supershift Assay
In vitro translated wild-type or mutated human VDR and human
RXR proteins were generated by coupled in vitro transcription/
translation using rabbit reticulocyte lysate as recommended by the
supplier (Promega, Madison, WI). Protein batches were quantified
by test-translations in the presence of [35S]methionine. The specific
concentrations of the receptor proteins were adjusted to approxi-
mately 4 ng/l after taking the individual number of methionine
residues per protein into account. Bacterial overexpression of GST-
TIF2646-926 or GST alone (as a control) was obtained from the E. coli
BL21(DE3)pLysS strain (Stratagene) containing the respective ex-
pression plasmids. Overexpression was stimulated with 0.25 mM
isopropyl--D-thio-galactopyranoside for 3 hr at 37C, and the pro-
teins were purified and immobilized on glutathione-Sepharose 4B
beads (Amersham-Pharmacia) according to the manufacturer’s pro-
tocol. Proteins were eluted in the presence of glutathione. For su-
pershift assays, in vitro translated VDR-RXR heterodimers were in-
cubated with saturating concentrations of 1,25(OH)2D3 or its
analogs for 15 min at room temperature in a total volume of 20 lFigure 7. Critical Changes of the LBD-TEI-9647 Complex
binding buffer (10 mM HEPES [pH 7.9], 1 mM DTT, 0.2 g/l
During 6.0 ns MD simulations, the backbone (N, C, C, O) rmsd of poly(dI-C), and 5% glycerol). The buffer had been adjusted to 150
residues 393–422 (A) and the distance between the C atoms of mM by addition of KCl. Then 3 g of bacterially expressed GST or
T415 and F422 (B) were compared for the complexes of VDRwt and GST-TIF2646-926 protein and 1 ng (approximately 50,000 cpm) of theVDRC403/C410 with 1,25(OH)2D3 or TEI-9647. The latter distance mea- 32P-labeled rat ANF DR3-type VDRE were added, and incubation
sures the length of helix 12 and is 10.8 A˚ in the X-ray structure of was continued for 20 min. Protein-DNA complexes were resolved
the VDRwt-1,25(OH)2D3-complex [7]. through 8% nondenaturing polyacrylamide gels in 0.5 TBE (45 mM
Tris, 45 mM boric acid, 1 mM EDTA [pH 8.3]). The gels were dried,
exposed to a Fuji MP2040S imager screen (Fuji, Tokyo, Japan), and
analog ZK168281 [12] was provided by Dr. Andreas Steinmeyer monitored on a Fuji FLA3000 reader.
(Schering AG, Berlin, Germany), and the 26,23-lactone analog TEI-
9647 [16] was a gift from Dr. Seiichi Ishizuka (Teijin Institute for Bio- Limited Protease Digestion Assay
Medical Research, Tokyo, Japan). All compounds were dissolved In vitro translated, 35S-labeled VDR protein (2.5 l) was incubated
in 2-propanol; further dilutions were made in DMSO (for in vitro with the appropriate ligand for 15 min at room temperature in 10 l
assays) or in ethanol (for cell culture assays). 50 mM Tris-HCl (pH 7.9). Trypsin (Promega, final concentration 20
ng/l) was then added, and the mixtures were further incubated for
DNA Constructs 15 min at room temperature. The digestion reactions were stopped
The full-length cDNAs for human VDR [26] and human RXR [27] by adding 10 l protein gel loading buffer (0.25 M Tris [pH 6.8],
were subcloned into the SV40 promoter-driven pSG5 expression 20% glycerol, 5% mercaptoethanol, 2% SDS, 0.025% bromophenol
vector (Stratagene, La Jolla, CA). The same constructs were used blue). The samples were denatured at 85C for 3 min and electropho-
for both T7 RNA polymerase-driven in vitro transcription/translation resed through 15% SDS-polyacrylamide gels. The gels were dried,
of the respective cDNAs and for viral promoter-driven overexpres- exposed to a Fuji MP2040S imager screen, and monitored on a Fuji
sion of the respective proteins in mammalian cells. The point mu- FLA3000 reader.
tants of VDR were generated using the QuikChange Point Mutagene-
sis Kit (Stratagene) and confirmed by sequencing. The luciferase MD Simulations
reporter gene was driven by four copies of the rat ANF DR3-type The initial coordinates for the MD simulations were obtained from
binding site (core sequence AGAGGTCATGAAGGACA) fused to the the X-ray crystal structure of the VDR LBD-1,25(OH)2D3 complex
tk promoter. The NR interaction domain of human TIF2 (spanning (Protein Data Bank code 1DB1) determined to 1.8 A˚ resolution [7].
amino acids 646 to 926) [28] was subcloned into the GST fusion The missing amino acid residues of the X-ray structure (residues
vector pGEX (Amersham-Pharmacia, Uppsala, Sweden). 118, 119, 375–377, and 424–427) were built using the Quanta98
molecular modeling package (Molecular Simulations Inc., San
Diego, CA). The four residues missing from the C terminus (424–427)Transfection and Luciferase Reporter Gene Assays
Ros17/2.8 (rat osteosarcoma), MG-63 (human osteosarcoma), REK were built in an -helical conformation (φ  57, 	  47). The
two VDR antagonists, ZK168281 and TEI-9647, were docked to the(rat epidermal keratinocytes), HaCaT (human immortalized keratino-
cytes), and MCF-7 (human breast cancer) cells were seeded into ligand binding site of LBD using the locally enhanced sampling
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method, which is a mean-field technique providing the ability to 10. Freedman, L.P. (1999). Increasing the complexity of coactivation
in nuclear receptor signaling. Cell 97, 5–8.focus on the interesting part of the system. Crystallographic water
molecules were included in simulation systems. The side chains of 11. Carlberg, C., and Mourin˜o, A. (2003). New vitamin D receptor
ligands. Expert Opin. Ther. Patents 13, 761–772.the C403S/C410N double mutant LBD were built using the C and
S atoms of the cysteines mutated. For the MD simulations, the 12. Bury, Y., Steinmeyer, A., and Carlberg, C. (2000). Structure activ-
ity relationship of carboxylic ester antagonists of the vitamin D3protein-ligand complexes were solvated by 10,779 TIP3P water mol-
ecules in a periodic box of 69  61  87 A˚. The water molecules receptor. Mol. Pharmacol. 58, 1067–1074.
13. Macias-Gonzalez, M., Samenfeld, P., Perakyla, M., and Carl-of the complexes were first energy-minimized for 2000 steps, heated
to 300 K in 10 ps, and equilibrated by 40 ps at a constant temperature berg, C. (2003). Corepressor excess shifts the two-side chain
vitamin D analog Gemini from an agonist to an inverse agonistof 300 K and pressure of 1 atm. The production simulations of 6 ns
were then started. In the simulations, the electrostatics were treated of the vitamin D receptor. Mol. Endocrinol. 17, 2028–2038.
14. Toell, A., Gonzalez, M.M., Ruf, D., Steinmeyer, A., Ishizuka, S.,using the particle-mesh Ewald method. A timestep of 1.5 fs was
used, and bonds involving hydrogen atoms were constrained to their and Carlberg, C. (2001). Different molecular mechanisms of vita-
min D3 receptor antagonists. Mol. Pharmacol. 59, 1478–1485.equilibrium lengths using the SHAKE algorithm. From the production
simulations, structures were saved every 0.75 ps for analyses, which 15. Herdick, M., Steinmeyer, A., and Carlberg, C. (2000). Antagonis-
tic action of a 25-carboxylic ester analogue of 1,25-dihydroxy-were done using the carnal and ptraj programs of the AMBER7.0
simulation package (University of California, San Francisco, CA). The vitamin D3 is mediated by a lack of ligand-induced vitamin D
receptor interaction with coactivators. J. Biol. Chem. 275,simulations were done using the PMEMD 3.03 program (University of
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two-stage RESP [30] fit at the HF/6-31G* level using ligand geome- human leukemia cells (HL-60) induced by 1,25-dihydroxyvita-
min D3. J. Biol. Chem. 274, 16392–16399.tries optimized with the semiempirical PM3 method using the
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